The new report by Expert Market Research titled, ‘Global Exocrine Pancreatic Insufficiency Treatment Market Report and Forecast 2021-2026’, gives an in-depth analysis of the global exocrine pancreatic insufficiency treatment market Trends, assessing the market based on its segments like disease management, diagnosis, and major regions.
The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analyzing the market based on the SWOT and Porter’s Five Forces models.
Request a free sample copy in PDF or view the report summary@ https://www.expertmarketresearch.com/reports/exocrine-pancreatic-insufficiency-treatment-market/requestsample
The key highlights of the report include:
Market Overview (2016-2026)
- Historical Market Size (2020): USD 3.6 Billion
- Forecast CAGR (2021-2026): 8.27%
- Forecast Market Size (2026): USD 5.8 Billion
The growth in the market is being driven by the rising demand for effectual treatments against exocrine pancreatic insufficiency caused by increasing prevalence of chronic pancreatic and cystic fibrosis amongst the geriatric populations, infants, and young adults.
Furthermore, owing to the sedentary lifestyles and unhealthy eating habits, the spur in the global cases of diabetes has become a leading cause of exocrine pancreatic insufficiency, thereby invigorating the market for EPI treatments.
Industry Definition and Segmentation
Exocrine Pancreatic Insufficiency (EPI) refers to a medical condition characterized by the inability to properly digest food due to insufficient levels of digestive enzymes produced by pancreas.
The disease is most commonly detected by clinical tests such as blood, stool, malabsorption, and pancreatic function tests.
Explore the full report with the table of contents@ https://www.expertmarketresearch.com/reports/exocrine-pancreatic-insufficiency-treatment-market
On the basis of disease management, the market can be divided into:
- Nutritional Management
- Pancreatic Enzyme Replacement Therapy (PERT)
- Lifestyle Modifications approach
Based on diagnosis, the market can be segmented into:
- Magnetic Resonance Imaging (MRI)
- CT Scanning
- Endoscopic ultra-sonography (EUS)
- Blood Tests
The regional markets for the product include:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
The market is anticipated to be driven by the rising focus on pharmaceutical research and development (R&D) for an effective treatment method is significantly contributing to the overall growth of the market.
In order to address the increasing demand for the treatment of exocrine pancreatic insufficiency, key industry players, in conjunction with governing agencies, are significantly contributing towards the development of a cure, and hence pushing the growth of the market.
Moreover, pancreatic enzyme replacement therapy (PERT) to aid in the digestion and for the absorption of fats is anticipated to hold a substantial share in the overall growth of the market owing to its status as a conventional therapy.
Key Market Players
The major players in the market are AbbVie Inc., Janssen Global Services, LLC, Chiesi Farmaceutici S.p.A., Nordmark Arzneimittel GmbH and Co. KG, Digestive Care, Inc, Cilian AG, Anthera Pharmaceuticals, Inc., Allergan plc., First Wave BioPharma, Inc. (AzurRx), and Aptalis Pharma Inc., among others.
The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.
Expert Market Research (EMR) is leading market research company with clients across the globe. Through comprehensive data collection and skilful analysis and interpretation of data, the company offers its clients extensive, latest and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.
EMR customises syndicated reports according to clients’ requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.
Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.
Company Name: Claight Corporation
Contact Person: Sophia Grace, Business Consultant
Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA